|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokinetic in- teraction between ivabradine and carbamazepine in healthy volunteers显示文摘 | Vlase L Neag M Popa A etal | 2011 | J Clin Pharm Ther2011，36，2： | 1 |
| 2 | Localization of MV-algebras and lu-groups显示文摘 | Bu§neag D Piciu D | 2003 | Algebra univers2003，50，： | 1 |
| 3 | Compact Variable Gain Amplifier for a muhistandard WLAN/WiMAX/LTE receiver 显示文摘 | ONET R NEAG M KOVACS I | 2014 | IEEE Transactions on Circuits and Systems I2014，61，1： | 1 |
| 4 | Overview of the microbiota in the gut-liver axis in viral B and C hepatitis显示文摘Viral B and C hepatitis are a major current health issue,both diseases having a chronic damaging effect on the liver and its functions.Chronic liver disease can lead to even more severe and life-threatening conditions,such as liver cirrhosis and hepatocellular carcinoma.Recent years have uncovered an important interplay between the liver and the gut microbiome:the gut-liver axis.Hepatitis B and C infections often cause alterations in the gut microbiota by lowering the levels of‘protective’gut microorganisms and,by doing so,hinder the microbiota ability to boost the immune response.Treatments aimed at restoring the gut microbiota balance may provide a valuable addition to current practice therapies and may help limit the chronic changes observed in the liver of hepatitis B and C patients.This review aims to summarize the current knowledge on the anatofunctional axis between the gut and liver and to highlight the influence that hepatitis B and C viruses have on the microbiota balance,as well as the influence of treatments aimed at restoring the gut microbiota on infected livers and disease progression. | Maria Adriana Neag Andrei Otto Mitre Adrian Catinean Anca Dana Buzoianu | 2021 | World Journal of Gastroenterology2021，27，43： | 1 |
| 5 | Blind Fre- quency-Selective I/Q Mismatch Compensation Using Subband Processing显示文摘 | KIREI B S NEAG M G TOPA M D | 2012 | Circuits and Systems II: Express Briefs IEEE Transactions on2012，59，5： | 1 |
| 6 | Microstructurc and flow behavior during backward extrusion of semi-solid 7075 aluminium alloy 显示文摘 | NEAG A FAVIER V BIGOT R POP M | 2012 | Journal of Materials Processing Technology2012，212，： | 1 |
| 7 | Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers显示文摘 | VLASE L NEAG M POPA A | 2011 | J Clin Pharm and Ther2011，36，2： | 1 |
| 8 | Microstructure and flow behaviour during backward extrusion of semi-solid 7075 aluminium alloy显示文摘 | Adriana Neag Véronique Favier Régis Bigot Mariana Pop | 2012 | Journal of Materials Processing Tech2012，，7： | 1 |
| 9 | Microstructure and flow behaviour during backward extrusion of semi-solid 7075 aluminium alloy显示文摘 | NEAG A FAVIER V BIGOT R POP M | | 0，，： | 1 |
| 10 | Effect of fluoxetine on the pharmacokinetics of lansoprazole:a two-treatment period study in healthy male subjects显示文摘 | Vlase L Popa A Neag M | 2011 | Clin Drug Investig2011，31，： | 1 |
| 11 | A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers显示文摘 | Briciu C Neag M Muntean D | 2014 | J Clin Pharm Ther2014，39，5： | 1 |
| 12 | On the Usage of RFID Tags for Tracking and Monitoring of Shipped Perishable Goods显示文摘 | Vladimir Todorovic Marius Neag Milovan Lazarevic | 2014 | Procedia Engineering2014，，： | 1 |
| 13 | The role of extensibility in software standards for automatic test systems显示文摘 | Lopes T P Neag I A Ralph J E | 2005 | IEEE AUTOTESTCON2005，，： | 1 |
| 14 | Blind frequency-selective I/Q mismatch using subband processing显示文摘 | Kirei B S Neag M G Topa M D | 2012 | IEEE Circuit and Systems H: Express Brief2012，59，5： | 1 |
| 15 | Microstructure and flow behavior during backward extrusion of semi-solid 7075 aluminum alloy显示文摘 | Adriana Neag Veronique Favier Regis Bigot | 2012 | 2012，，07： | 1 |
| 16 | A Unified Interface for Signal - oriented Control Of Instruments and Switches 显示文摘 | Stefan Gal Ion A Neag | 2002 | IEEEAUTOTESTCON Proceedings2002，，： | 1 |
| 17 | Gastrointestinal microbiota:A predictor of COVID-19 severity?显示文摘Coronavirus disease 2019(COVID-19),caused by a severe acute respiratory syndrome coronavirus 2 infection,has raised serious concerns worldwide over the past 3 years.The severity and clinical course of COVID-19 depends on many factors(e.g.,associated comorbidities,age,etc)and may have various clinical and imaging findings,which raises management concerns.Gut microbiota composition is known to influence respiratory disease,and respiratory viral infection can also influence gut microbiota.Gut and lung microbiota and their relationship(gut-lung axis)can act as modulators of inflammation.Modulating the intestinal microbiota,by improving its composition and diversity through nutraceutical agents,can have a positive impact in the prophylaxis/treatment of COVID-19. | Maria Adriana Neag Damiana-Maria Vulturar Diana Gherman Codrin-Constantin Burlacu Doina Adina Todea Anca Dana Buzoianu | 2022 | World Journal of Gastroenterology2022，28，45： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员